Astrazeneca (AZN) EPS (Weighted Average and Diluted) Growth (3y) (2012 - 2025)
Astrazeneca (AZN) EPS (Weighted Average and Diluted) Growth (3y) (2012 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
- |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
76.98% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
318.57% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
44.22% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-52.54% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-14.16% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
26.25% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-21.46% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
6.98% |
| 10 |
Astrazeneca |
72.15 Bn |
64.21 Bn |
12.61 Bn |
- |
| Date | Value |
|---|
| Dec 31, 2025 |
36.96% |
| Sep 30, 2025 |
15.55% |
| Jun 30, 2025 |
89.70% |
| Dec 31, 2024 |
63.41% |
| Sep 30, 2024 |
-6.13% |
| Jun 30, 2024 |
43.46% |
| Mar 31, 2024 |
14.51% |
| Dec 31, 2023 |
1.19% |
| Sep 30, 2023 |
21.55% |
| Jun 30, 2023 |
26.35% |
| Mar 31, 2023 |
38.14% |
| Dec 31, 2022 |
47.21% |
| Sep 30, 2022 |
81.97% |
| Jun 30, 2022 |
45.45% |
| Mar 31, 2022 |
-18.98% |
| Dec 31, 2021 |
-35.50% |
| Sep 30, 2021 |
61.72% |
| Jun 30, 2021 |
26.13% |
| Dec 31, 2020 |
-9.63% |
| Jun 30, 2020 |
27.08% |
